Huons said that it would market the Israeli medical device company Insightec's ExAblate Neuro, a magnetic resonance imaging (MRI)-guided focused ultrasound treatment system, in Korea.
|Huons CEO Um Key-an (right) and Insightec Vice President Roni Yagel hold up their agreement at Huons headquarters in Seongnam, Gyeonggi Province, on Thursday.|
The device uses ultrasound, which is known to be used only for diagnostic or skincare, to treat cerebral neurological diseases. It is the only device in the world that has received approval from the U.S. Food and Drug Administration (FDA) to treat such conditions.
Insightec is operating an ExAblate neuro center in 66 major hospitals around the world, including those in the U.S., Europe and Asia.
Huons plans to strengthen its competitiveness in the local neurosurgery market through the territory sales contract with Insightec. Also, the company plans to increase indications for the device by collaborating with leading university hospitals in Korea and various joint researches in the future.
"With the introduction of Insightec's devices, Huons expects to become the leading company in the cerebral neurological disease market and set new standards for treatment," Huons CEO Um Key-an said.
Insightec also said, "We have signed a sales contract with Huons to enter the Korean neurosurgery market. We are confident that we will revolutionize Korea's cerebral neurological disease market through the pharmaceutical technology and sales know-how accumulated by Huons and the expansion of future market implications for Insightec's ExAblate Neuro."
<© Korea Biomedical Review, All rights reserved.>